Peter the Bridge, Saint Petersburg, Russia

News from NEOMED

GSK and NEOMED Launch $2M Discovery Fund to Accelerate Novel Science and Technologies in Quebec

21 June 2017| No Comments
The fund aims to advance and de-risk innovative and early stage human therapeutic discoveries arising from academic and research institutes in Quebec Laval, QC, June 21, 2017 – GlaxoSmithKline Inc. (GSK) and NEOMED Institute (NEOMED) are pleased to announce that they

Read complete news


20 June 2017|Announcement| No Comments
San Diego, June 20, 2017 – The NEOMED Institute and GIP GENOPOLE – the promoters of two successful national models for the development of biotechnology ecosystems - today announced the signature of a strategic cooperation agreement to explore and develop common initiatives to establish and sustain a collaborati

Read complete news

NEOMED Institute Announces Publication and Clinical Update for NEO6860 an Oral Therapeutic in Development for the Treatment of Chronic Pain

28 March 2017|Announcement| No Comments
- NEO6860 is a promising TRPV1 antagonist designed to avoid on-target side effects - Target engagement and safety profile established in recently published Phase 1 study1 - Promising preliminary results from Phase 2 Study completed in Q1/2017 Montreal, Quebec - March 28

Read complete news

BELLUS Health and NEOMED Institute Announce an Exclusive Worldwide License Agreement for the Development of a Treatment for Chronic Cough

28 February 2017| No Comments
MONTREAL, February 28, 2017 – BELLUS Health (TSX:BLU), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical needs, and NEOMED Institute (NEOMED), a not-for-profit organization bridging the gap between basic research and the commercialization of new drugs, today announced tha

Read complete news

© 2017 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia